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Abstract: Diazepinomicin is a dibenzodiazepine alkaloid with an unusual structure among 
the known microbial metabolites discovered so far. Diazepinomicin was isolated from the 
marine sponge-associated strain Micromonospora sp. RV115 and was identified by 
spectroscopic analysis and by comparison to literature data. In addition to its interesting 
preclinical broad-spectrum antitumor potential, we report here new antioxidant and  
anti-protease activities for this compound. Using the ferric reducing antioxidant power 
(FRAP) assay, a strong antioxidant potential of diazepinomicin was demonstrated. 
Moreover, diazepinomicin showed a significant antioxidant and protective capacity from 
genomic damage induced by the reactive oxygen species hydrogen peroxide in human 
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kidney (HK-2) and human promyelocytic (HL-60) cell lines. Additionally, diazepinomicin 
inhibited the proteases rhodesain and cathepsin L at an IC50 of 70–90 µM. It also showed 
antiparasitic activity against trypomastigote forms of Trypanosoma brucei with an IC50 of 
13.5 µM. These results showed unprecedented antioxidant and anti-protease activities of 
diazepinomicin, thus further highlighting its potential as a future drug candidate.  
Keywords: diazepinomicin; anti-protease; antioxidant; actinomycetes; Micromonospora 
 
1. Introduction 
Diazepinomicin is a farnesylated dibenzodiazepinone that was discovered by Thallion’s DECIPHER® 
platform [1] and was isolated for the first time from the marine Micromonospora strain DPJ12 cultivated 
from the ascidian Didemnum proliferum at Shishijima Island, Japan [2]. Its biosynthetic pathway was 
studied by McAlpine [3] and continued by Ratnayake [4]. Diazepinomicin is of considerable interest, 
owing to its broad-spectrum antitumor activity [5]. It showed a high inhibition potential in cancer cells 
in vitro, in tumor xenografts in vivo, and a high efficacy in advanced cancer patients, which was 
confirmed in clinical investigations. This activity is mediated by selective binding to the peripheral 
benzodiazepine receptor (PBR), resulting in tumor apoptosis and inhibition of the Ras/MAP kinase 
signaling pathway, which is involved in cellular proliferation and migration [6]. For these reasons, 
diazepinomicin is currently in phase II clinical trials after having successfully passed phase I clinical 
trials for Thallion pharmaceuticals.  
Free radicals and other reactive oxygen/nitrogen/chlorine species contribute to the development of 
several age-related diseases and to the aging process itself by causing oxidative stress and oxidative 
damage [7,8]. The implication of oxidative stress in the history of several acute and chronic clinical 
disorders, such as cancer, atherosclerosis and diabetes, led to the suggestion that antioxidants can be 
prophylactic agents against such diseases [9–11]. Antioxidant drugs protect from the tissue damage 
induced by free radicals by preventing their formation, scavenging them, or by promoting their 
decomposition [12]. Natural products, such as prenylated toluquinones and hydroquinones, were 
derived from marine sources including sponges, algae and marine microbes, and were found to exhibit 
good antioxidant properties [13–15].  
Proteases are a big family of enzymes that are essential for growth and pathogenicity of bacteria, 
viruses and parasites. Therefore, they represent new potential targets for anti-infective drugs [16]. 
Rhodesain is expressed by the parasite Trypanosoma brucei rhodesiense, which is the causative agent 
of trypanosomiasis. Human cysteine cathepsins were reported to be associated with different mammalian 
tumors, suggesting their involvement in metastasis, angiogenesis and tumor progression [17]. Several 
protease inhibitors are in clinical phases for treatment of many diseases such as hypertension, diabetes, 
infectious diseases and cancer [18,19]. 
The goal of this study was to obtain deeper insights into the activity profile of diazepinomicin.  
The antioxidant activity of diazepinomicin was investigated using the chemical ferric reducing 
antioxidant power (FRAP) method and a cell-based assay in the human promyelocytic cell line HL-60. 
The cell vitality and protection from oxidative genomic damage was assessed in human kidney HK-2 
Mar. Drugs 2012, 10 2210 
 
cells. Moreover, the effect on the proteases rhodesain and cathepsin L was also examined by 
enzymatic and HPLC based assays. This work has added new potential insights to the medicinal use  
of diazepinomicin. 
2. Results and Discussion 
Micromonospora sp. RV115 strain was isolated from the sponge Aplysina aerophoba, which had 
been collected from Rovinj, Croatia [20]. The strain was fermented in Bennett’s medium, and the 
secondary metabolites were collected via XAD-16 resin, which was then eluted with acetone-methanol. 
After dissolving the residue in water and extraction with ethyl acetate, the ethyl acetate extract was 
subjected to normal-phase flash chromatography with cyclohexane:ethyl acetate mixture and to final 
purification with reversed-phase HPLC using MeOH:H2O mixture supplemented with 0.05% formic 
acid to give compound 1 (11.1 mg). HR-ESIMS (FTICR) analysis showed that compound 1 has an  
[M + H]+ at 463.2528 and a molecular formula of C28H35N2O4. A database search using MarinLit 
database (2012) suggested that this mass coincided with that of diazepinomicin [2]. Analysis of  
1H-NMR data, as well as 2D NMR data, including COSY, HSQC and HMBC spectra, and comparison 
with those in the literature confirmed the structure of 1 as diazepinomicin (Figure 1).  
Figure 1. Structure of diazepinomicin (1). 
 
2.1. Cytotoxicity of Diazepinomicin in Human Kidney Cells (HK-2)  
Because reactive oxygen species (ROS) are an important mediator of renal injury [21,22], 
diazepinomicin (DZP) cytotoxicity was examined here in the human kidney cell line, HK-2, which was 
also used by others in oxidative stress studies [21]. HK-2 cells were treated with concentrations of  
2–25 µM diazepinomicin for 24 h. A small and non-significant (p > 0.05) decrease in cell viability of 
less than 5% was observed, suggesting that diazepinomicin is not toxic to HK-2 cells.  
2.2. Antioxidant Potential of Diazepinomicin  
The intrinsic antioxidant capacity of diazepinomicin was first assessed using the cell-free system, 
FRAP (Figure 2). The FRAP assay is based on the measurement of the ability of the substance to 
reduce Fe3+ to Fe2+, and it directly measures the reducing capacity of the compound, which is 
considered to be an important parameter for antioxidant function. This method reliably investigates the 
total antioxidant activity and has been widely used for a rapid assessment of the antioxidant potential 
of various food, beverages and natural products [23]. Our results demonstrate that diazepinomicin 
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exhibited significant antioxidant activity, with 30 nM of diazepinomicin showing an equal potential to 
50 µM tempol, indicating the strong antioxidant potential of diazepinomicin.  
Figure 2. Ferric reducing antioxidant power (FRAP) of cell-free solutions of diazepinomicin 
assessed by the photometric quantification (* = significant vs. control). 
 
We further examined the antioxidant potential of diazepinomicin in vitro using the dye  
2′,7′-dichlorodihydrofluorescein diacetate (H2DCF-DA). Acetate groups are removed from the 
molecule by cellular esterases upon entry into live cells, where the dye is oxidized to the fluorescent 
product dichlorofluorescein (DCF) in the presence of ROS and represents a marker for oxidative 
stress. The human promyelocytic cell line HL-60 was used here, because of its high sensitivity for 
oxidative stress. Cells were treated with diazepinomicin (10, 25 µM) in combination with 50 µM H2O2 
as an oxidative stress inducer for 30 min, and the DCF fluorescence was measured using flow 
cytometric analysis (Figure 3). While diazepinomicin alone did not alter the ROS level in the cells, 
H2O2 induced an increase, which was significantly reduced by treatment with 25 µM of diazepinomicin. 
In this test, diazepinomicin was used at higher concentrations to compensate for the artificial oxidative 
stress effect induced by 50 µM H2O2. These results confirmed the assumption that diazepinomicin has 
high antioxidant potential. This cell-based assay, in contrast to the cell-free chemical assay FRAP 
(Figure 2), detects only the antioxidant compounds that can penetrate the cellular membranes of living 
cells and inhibit the ROS-mediated oxidation intracellularly. Marine natural products, such as 
aaptamine, isoaaptamine and curcudiol exhibited antioxidant potential in chemical assays but were not 
able to scavenge free radicals in cell-based assays [24]. This could be explained by the inability to 
penetrate the cell membrane, or that they are not capable of preventing 2′,7′-dichlorodihydrofluorescein 
oxidation intracellularly. Our results highlight the antioxidant potential of diazepinomicin by chemical 
and cell-based assays. 
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Figure 3. Flow cytometric analysis for the antioxidant capacity of diazepinomicin in HL-60 
cells treated with 50 µM H2O2 and diazepinomicin for 30 min (Δ = non significant vs. 
control, * = significant vs. control and ≠ = significant vs. H2O2). 
 
2.3. Protective Effect of Diazepinomicin against Oxidative Stress-Induced Cell Death in HK-2 Cells 
Next, we investigated the protective effect of diazepinomicin against oxidative stress-induced cell 
death using H2O2. HK-2 cells were treated with 100 µM H2O2 in combination with different 
concentrations of diazepinomicin for 24 h (Table 1).  
Table 1. Cell death after 24 h incubation of HK-2 cells with 100 µM H2O2, and different 
concentrations of diazepinomicin (2–25 µM) and 50 µM tempol as a positive control for 
antioxidant activity. (Δ = non significant increase in cell death, * = significant increase in 
cell death and ≠ = significant decrease in cell death). 
Test substance Cell death (% dead cells) 
Control 4 ± 1.0 
25 µM DZP 4.5 ± 0.0 (Δ vs. control ) 
50 µM tempol 9.7 ± 4.3  
100 µM H2O2 21 ± 5.8 (* vs. control) 
100 µM H2O2 + 2 µM DZP 6.5 ± 4.4 (≠ vs. H2O2) 
100 µM H2O2 + 5 µM DZP 7.5 ± 1.8 (≠ vs. H2O2) 
100 µM H2O2 + 10 µM DZP 5.3 ± 1.0 (≠ vs. H2O2) 
100 µM H2O2 + 25 µM DZP 6.3 ± 2.5 (≠ vs. H2O2) 
100 µM H2O2 + 50 µM tempol 14.7 ± 5.8 
Our results showed that diazepinomicin (or tempol as a positive control) did not cause significant 
toxicity, while H2O2 led to an increased number of dead cells, which was significantly reduced in the 
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presence of diazepinomicin. These results indicate that diazepinomicin protected HK-2 cells from 
H2O2-induced injury by inhibiting oxidative damage and, ultimately, cell death. 
Further investigations included the examination of the protective power of diazepinomicin against 
oxidative damage of DNA induced by H2O2 using the alkaline version of the comet assay (Figure 4). 
This endpoint detects single and double strand breaks, as well as alkali labile sites, on an individual 
cell basis. For this, HK-2 cells were treated with diazepinomicin or tempol in combination with 100 µM 
H2O2 for 30 min. While diazepinomicin alone did not cause elevated DNA damage, H2O2 yielded an 
increased percentage of DNA in the comet tail, which is the region containing damaged DNA. The 
H2O2-induced DNA damage was reduced in a dose-dependent fashion by a combination with tempol 
or with diazepinomicin. 
Figure 4. DNA damage (% DNA in tail) measured with the comet assay after treatment of 
HK-2 cells with 100 µM H2O2, and diazepinomicin (5 & 15 µM) and 50 µM tempol for  
30 min. (Δ = non significant vs. control, * = significant vs. control and ≠ = significant 
vs. H2O2). 
 
2.4. Antitrypanosomal and Anti-Protease Activities 
Diazepinomicin was tested for its antitrypanosomal activity against trypomastigote forms of 
Trypanosoma brucei brucei laboratory strain TC 221 at both 48 and 72 h time points. Diazepinomicin 
exhibited IC50 values of 13.57 and 17.06 µM, respectively, which has not been previously reported in 
the literature to our knowledge. Since diazepinomicin exhibited activity against Trypanosoma brucei, 
we tested the compound against the parasite’s protease rhodesain. Diazepinomicin showed 
concentration-dependent inhibition of the hydrolysis of the fluorogenic substrate Cbz-Phe-Arg-AMC 
(Figure 5). Few natural products with anti-protease activities have been reported from the marine 
environment. One such example are the new tetromycin derivatives, tetromycins 1–4, that were 
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isolated from Streptomyces axinellae Pol001T, which had been cultivated from the Mediterranean 
sponge Axinella polypoides. Tetromycins 3–4 exhibited protease inhibition activities against several 
cysteine proteases [25]. Furthermore, the peptide miraziridine A that was isolated from the marine 
sponge Theonella swinhoei, exhibited potent activity against cathepsin B [26]. In the present study, the 
assays with the protease rhodesain at three different substrate concentrations showed diazepinomicin to 
be a competitive inhibitor with respect to the substrate used (Figure 6). The dissociation constant Ki of 
inhibition of rhodesain was determined to be 98 µM. 
Figure 5. Progress curves of hydrolysis of the substrate Cbz-Phe-Arg-AMC (10 µM) in the 
absence or presence (from top to bottom) of diazepinomicin ([I] = 0.01 – 0.02 – 0.04 – 0.05 
– 0.06 – 0.08 – 0.1 mg/mL). 
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Figure 6. Dependency of IC50 values of the inhibition of rhodesain by diazepinomicin on 
substrate concentration. Increasing IC50 values at higher substrate concentrations shows 
diazepinomicin to be a competitive inhibitor. The Ki value (extrapolated IC50 at 0 substrate 
concentration) was determined to be 0.0456 mg/mL (98 µM). 
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Since rhodesain is a parasite’s analog of the human cysteine cathepsins, which are involved in 
cancer progression and metastasis [27–30], we also tested the activity of diazepinomicin against 
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human cathepsin L. Diazepinomicin showed similar activity (IC50 = 72.4 ± 5.3 µM at a substrate 
concentration of 6.25 µM from four independent assays). Since diazepinomicin quenches fluorescence 
of the hydrolysis product AMC (inner filter effect), correction assays were performed according to 
Ludewig et al. [31]. In order to verify the inhibition, we also detected the substrate hydrolysis by an 
HPLC-based method. The cathepsin L catalyzed hydrolysis of the substrate (30 min incubation time, 
[S] = 6.25 µM) was quantified in absence and presence of different concentrations of diazepinomicin 
(20, 100 µM) after column chromatographic separation of the hydrolysis product and the substrate. 
These studies proved the inhibitory potency of diazepinomicin (45% inhibition at 20 µM; 64% at 
100 µM). We observed instability of the diazepinomicin DMSO stock solution (stored for more than 
4 weeks), which was possibly due to its oxidation. Assays with solutions that were not freshly 
prepared showed weaker inhibitory activity and IC50 values of 141 µM ± 20 µM (from six independent 
assays) against cathepsin L. This reduced inhibitory potency with non-freshly prepared stock solutions 
was also seen in the HPLC-based assays with only 26% inhibition at 20 µM, and 36% inhibition at 
80 µM diazepinomicin. 
In conclusion, diazepinomicin exhibited antioxidant capacity using two different strategies 
including cell-free and cell-based assays. Diazepinomicin was able to protect cells from toxicity and 
genomic damage induced by the strong oxidant H2O2. This antioxidant activity will add a new 
perspective on the use of diazepinomicin in chemoprevention therapy for different types of cancer. 
Moreover, diazepinomicin showed anti-protease activity against rhodesain and cathepsin L, which 
suggests that anti-protease activity may contribute to the anticancer and antitrypanosomal activities as 
one of the possible mechanism of actions. 
3. Experimental Section 
3.1. Cultivation and Purification  
Micromonospora sp. RV115 was isolated from the sponge Aplysina aerophoba, which was 
collected from the Mediterranean Sea [20]. Micromonospora strain RV115 was fermented in 25 × 1 L 
baffled flasks, each containing 200 mL of Bennett’s broth (glucose 10 g/L, beef extract 0.77 g/L, yeast 
extract 1 g/L, NZ-amine 2 g/L, XAD 16 resin 20 g/L in 50% ASW, pH 7.3) at 28 °C for 9 days with 
shaking at 180 rpm. The harvested culture broth was centrifuged (9000 rpm, 10 min, 2 °C) and the 
mycelium, together with the XAD 16, were extracted with acetone/methanol (3/7, 3 × 500 mL). The 
combined extracts were concentrated under vacuum, resuspended in deionized water (250 mL) and 
extracted with ethyl acetate (3 × 250 mL, pH 5). The ethyl acetate extract was purified by normal 
phase flash chromatography (cyclohexane, ethyl acetate starting with 100% cyclohexane, 20, 40, 60, 
80 up to 100% ethyl acetate), followed by purification of the fraction with 40% ethyl acetate with 
reverse phase HPLC (Nucleodur 100-5 C18 ec), using a gradient 80%–100% methanol/water 
containing 0.05% formic acid over 20 min to yield 11.1 mg of diazepinomicin. 
3.2. Ferric Reducing Antioxidant Power (FRAP) Assay 
Total antioxidant activity was measured according to Benzie and Strain [32]. In brief, the FRAP 
solution was freshly prepared (25 mL of 300 mM acetate buffer, pH 3.6, 2.5 mL of 20 mM ferric 
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chloride hexahydrate dissolved in distilled water, and 2.5 mL of 10 mM 2,4,6-tripyridyl-s-triazine 
(TPTZ) dissolved in 40 mM HCl). 20 μL of diazepinomicin in methanol (1 mg/mL) was mixed with 
600 µL of the FRAP solution and 180 µL of water. Absorbance was measured at 595 nm after 6 min of 
incubation at room temperature by a spectrophotometer (Bio-Tek, Model Uvikon XL) against a blank 
of distilled water. Tempol was tested at the final concentration of 50 μM and used as the reference 
compound. FRAP values were obtained by comparing the absorbance change at 595 nm in test 
reaction mixtures with those containing ferrous ions in known concentrations. Absorbance changes are 
linear over a wide concentration range with antioxidant mixtures. 
3.3. Cell Culture Maintenance 
HK-2, a human kidney cell line with many properties of proximal tubular cells, was obtained from 
Dr. G. Garibotto, Department of Internal Medicine and Urology, University of Genoa, Italy. Cells were 
cultured two times per week at 37 °C in DMEM/F12 medium (PAA Laboratories GmbH, Pasching, 
Austria) supplemented with 5% fetal calf serum, 2 mM of L-glutamine, 1% antibiotics (50 U/mL 
penicillin, 50 mg/mL streptomycin), 10 µg/L epidermal growth factor, 5 µg/L hydrocortisone, 5 µg/L 
sodium selenate, 5 ng/L bovine pituitary extract, 5 mg/L transferrin, and 5 mg/L insulin and 5 ng/L T3.  
HL-60, a human promyelocytic cell line was donated by Prof. R. Schinzel, Vasopharm GmbH, 
Würzburg, Germany. HL-60 cells were cultured three times per week at 37 °C, 5% (v/v) CO2 in RPMI 
1640 medium, supplemented with 10% (v/v) fetal bovine serum (FBS), 1% (w/v) L-glutamine and 
0.4% (w/v) antibiotics (50 U/mL penicillin, and 50 mg/mL streptomycin).  
3.4. Flow Cytometric Quantification of Antioxidant Activity 
The potential of antioxidant activity was estimated using the probe 2′,7′-dichlorodihydrofluorescein 
diacetate (H2DCF-DA). The cell-permeable H2DCF-DA is non-fluorescent until the acetate groups are 
removed by intracellular esterases and until oxidation occurs within the cell, leading to the fluorescent 
product dichlorofluorescein (DCF). Oxidation of this probe can be detected by monitoring the increase 
in fluorescence using flow cytometer with filters appropriate for fluorescein (FITC). HL-60 cells (5 × 105) 
were seeded in 25 cm2 flasks and incubated in medium containing 50 µM H2O2, 25 µM 
diazepinomicin or H2O2 with diazepinomicin (10 and 25 µM) for 30 min. At the last 10 min of the 
treatment, 10 μM H2DCF-DA were additionally loaded. Afterwards, the medium was removed, the 
cells were rinsed with PBS, and 1 mL of BSA/PBS was added per flask. Fluorescence was measured at 
λexc 475 nm; λem 525 nm. To determine the viability of the cells during the process, samples were 
subsequently incubated with 0.1% (v/v) 50 μM PI, incubated for 10 min at room temperature, and the 
fluorescence (λexc 538 nm, λem 590 nm) was measured. Results are expressed as the ratio DCF 
(dichlorofluorescein) fluorescence/PI fluorescence. 
3.5. Vitality Test 
The assay was performed as described by Schmitt et al. [33]. However, ethidium bromide was 
replaced with Gel RedBiotrend (Köln, Germany). Vitality staining was performed for the HK-2 cells 
treated with different concentrations of diazepinomicin (2 to 25 µM) for 24 h. 0.35 × 106 cells were 
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seeded in 25 cm2 flasks for 24 h in a control medium. After treatment with diazepinomicin or tempol 
as positive control, cells were harvested, and 70 μL of the cell suspension was stained with 30 μL 
staining solution. Twenty microliter of this mixture was applied to the slide, and the fractions of green and 
red cells in a total of 200 cells were counted at a 500-fold magnification with a fluorescence microscope. 
3.6. Comet Assay 
After treatment of HK-2 cells with 100 µM H2O2 alone, or with H2O2 and diazepinomicin (5 and  
15 µM), the cells were harvested, and 20 μL of the treated cell suspension were mixed with 180 μL of 
0.5% low melting agarose and added to fully frosted slides that had been covered with a bottom layer 
of 1% normal melting point agarose. The slides were incubated in lysis solution (2.5 M NaCl, 0.1 M 
EDTA, 0.01 M Tris and 1% Triton X-100, 10 g/L N-lauroylsarcosine sodium adjusted to pH 10 with 
NaOH) at 4 °C. After 1 h, the slides were washed and then placed in the electrophoresis solution (300 mM 
NaOH, 1 mM EDTA, pH > 13.0) for 20 min. The electrophoresis was conducted for 20 min at 25 V 
(1.1 V/cm) and 300 mA. The slides were neutralized in 0.4 M Tris buffer (pH 7.5) and then dehydrated 
in methanol for 10 min at −20 °C. The slides were left at 37 °C in an incubator to dry and then stored 
at room temperature. Before evaluation, 20 μL of Gel red /DABCO solution was added to each slide. 
Images of 50 randomly selected cells (25 per replicate slide) for each sample were analyzed with a 
fluorescence microscope (Labophot 2, Nikon, Germany) at 200-fold magnification using image 
analysis software (Komet 5, BFI Optilas, Germany). A representative picture of a damaged cell in the 
comet assay is inserted into Figure 4. While intact nuclear DNA remains in the head region of  
the cellular comet, damaged DNA moves faster during electrophoresis and, thus, forms the tail region 
of the cellular comet. The percentage of DNA in the tail region was used to quantify DNA  
damage-related migration. 
3.7. Statistics for Cell Based Assays 
Data from 3 independent experiments ± standard deviation are depicted. Statistical significance 
among multiple groups was tested with the Kruskal-Wallis test. Individual groups were then tested 
using the Mann Whitney U-test, and results were considered significant if the p-value was ≤ 0.05. 
3.8. Antitrypanosomal Activity 
Antitrypanosomal assay was done as described by Huber and Koella [34]. In brief, trypomastigote 
forms of Trypanosoma brucei brucei laboratory strain TC 221 were cultured in Complete Baltz 
medium [35], and a defined number of parasites (104 trypanosomes per mL) were exposed in test 
chambers of 96-well plates to various concentrations of diazepinomicin (previously dissolved in 
DMSO) to make a final volume of 200 μL in duplicates. Trypanosomes in a culture medium as a 
positive control, and diazepinomicin without trypanosomes as a negative control were run 
simultaneously with each plate. After incubating the plates at 37 °C in an atmosphere of 5% CO2 for a 
total time period of 72 h, 20 μL of Alamar Blue was added and the activity was measured by light 
absorption using Microplate Reader MR 700 at a wavelength of 550 nm with a reference wave length 
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of 630 nm. First reading was done at 48 h and subsequently at 72 h. The effect of the test substances 
was quantified in IC50 values by linear interpolation of three independent measurements. 
3.9. Protease Assays 
The assays were performed as previously described [36]. In brief, the hydrolysis of Cbz-Phe-Arg-AMC 
by either rhodesain or human cathepsin L was detected continuously over a period of 10 min using a 
Varian Cary Eclipse spectrofluorometer (Varian, Darmstadt, Germany) with a microplate reader 
(excitation at 365 nm, emission at 460 nm, 25 °C). The following buffer solutions were used: 50 mM 
sodium acetate buffer, pH 5.5 containing 2 mM (cathepsin L), or 5 mM (rhodesain) DTT, 5 mM 
EDTA, 200 mM NaCl and 0.005% Brij 35. DMSO stock solutions of substrate and inhibitor were 
freshly prepared. DMSO alone (7.5% final concentration) was used as a negative control. 
For the HPLC based assay, the same conditions were used: the enzymatic hydrolysis of the 
substrate in absence or presence of diazepinomicin was stopped after 30 min by diluting the reaction 
with acetonitrile. The reaction mixtures (50 µL) were submitted to HPLC, and the amounts of AMC 
produced and of residual substrate Cbz-Phe-Arg-AMC were detected after separation using a Waters 
symmetry C18 column (3.5 µm, 4.6 × 75 mm) and a gradient with the solvents, A: phosphate buffer  
25 mM pH 6.0 with 10% methanol; and B: methanol (from 10% A/90% B to 100% A/0% B within  
40 min, flow 0.8 mL/min). A diode array detector (DAD) was used (210–400 nm). The AMC peak 
(retention time 2 min) was quantified (area under the curve, AUC) at 347 nm, whereas the substrate 
peak (retention time 30 min) was quantified at 326 nm. The percentage of inhibition by diazepinomicin 
was calculated for each experiment comparing the AUCs of the substrate peaks without enzyme, after 
30 min incubation of substrate and enzyme, after 30 min incubation of substrate, enzyme and inhibitor, 
and by comparing the AUCs of the AMC peaks after 30 min incubation of substrate and enzyme with 
those obtained after 30 min incubation of substrate, enzyme and inhibitor. Each experiment was 
performed in triplicate. 
4. Conclusions 
Our results showed that diazepinomicin exhibited antioxidant capacity using two different strategies 
including cell-free and cell-based assays. Diazepinomicin was able to protect cells from toxicity and 
genomic damage induced by the strong oxidant H2O2. This antioxidant activity will add a new 
perspective on the use of diazepinomicin in chemoprevention therapy for different types of cancer. 
Moreover, diazepinomicin showed anti-protease activity against rhodesain and cathepsin L, which 
suggests that anti-protease activity may contribute to the anticancer and antitrypanosomal activities as 
one of the possible mechanism of actions. 
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